Clinical Trials Directory

Trials / Completed

CompletedNCT02927795

OTIVACTO Spain Non Interventional Study

Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

Status
Completed
Phase
Study type
Observational
Enrollment
257 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC. Patients will be enrolled consecutively and will be followed over an observational period of approx. 6 weeks.

Detailed description

Purpose: Study Design:

Conditions

Timeline

Start date
2017-04-26
Primary completion
2018-09-18
Completion
2018-09-18
First posted
2016-10-07
Last updated
2019-09-30
Results posted
2019-09-30

Locations

79 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT02927795. Inclusion in this directory is not an endorsement.

OTIVACTO Spain Non Interventional Study (NCT02927795) · Clinical Trials Directory